PINK:IGNT « TheOTCInvestor.com TheOTCInvestor.com

Posts Tagged ‘PINK:IGNT’

Ingen (Pink Sheets: IGNT) Targets Underserved COPD Market with Oxyview

Tuesday, September 14th, 2010

Ingen Technologies, Inc. (Pink Sheets: IGNT) is targeting the large and underserved Chronic Obstructive Pulmonary Disease (COPD) market, alongside industry giants like AstraZeneca plc (NYSE: AZN) and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), with its Oxyview product line.

Targeting a Large and Growing Market

With the COPD market expected to grow to $23 billion by 2014, according to Research and Markets, many industry bellwethers ranging from AstraZeneca plc to Teva Pharmaceutical Industries Ltd. are targeting the industry with new drugs and devices designed to help relieve symptoms.

COPD is a disease that is characterized by the airways to the lungs narrowing, which causes shortness of breath, which gets worse over time in some cases. Often times, the disease is caused by noxious particles or gas, most often from tobacco smoking, which triggers an inflammatory response in the lung.

With an aging population of smokers facing such conditions, and an increase in smoking in some emerging markets in Asia and Latin America, the worldwide COPD problem costs the U.S. healthcare system more than $40 billion a year and is the fourth leading cause of death.

Treatments and Solutions for COPD

While COPD has no cure, there are many treatments on the market. Companies like AstraZeneca and Teva produce pharmaceutical solutions, but companies like Ingen Technologies (Pink Sheets: IGNT) provide the foundation for treatment via oxygen therapy.

Since COPD is characterized by a lack of oxygen entering the lungs, many patients receive pure oxygen through a nasal cannula in order to receive the oxygen levels required. These cannulas have traditionally been mass-produced in China, are uncomfortable and provide little added value.

Ingen Technologies has developed a revolutionary new oxygen cannula, called Oxyview that is far more comfortable and provides several value-added features. For instance, the Oxyview provides a gauge that confirms the flow of oxygen at the source in order to reassure patients concerned about an emptying oxygen tank.

Ingen’s Solutions Save Time and Money

Ingen Technologies’ SMART Oxyview cannulas are available at roughly the same price as traditional cannulas, while its oxygen readings can help dramatically reduce out-patient visits by oxygen providers like Lincare Holdings (LNCR) and Cardinal Health, Inc. (CAH).

With such a compelling value proposition, it is little surprise that Ingen has seen its sales move up last quarter. Meanwhile, efforts to reach out to military and international customers should also drive revenue moving forward. As a result, growth investors may want to take a close look at IGNT.

Tags: NASDAQ:TEVA, NYSE:AZN, PINK:IGNT
Posted in Insights | No Comments »

Ingen Technologies Signs Sales Contract With Healthstar Associates

Wednesday, September 8th, 2010

Ingen Technologies, Inc. (Pink Sheets: IGNT), a medical device maker focused on the respiratory industry and catering to homecare oxygen providers similar to Cardinal Health, Inc. (NYSE: CAH) and Lincare Holdings, Inc. (Nasdaq: LNCR), announced that it signed a sales contract with Healthstar Associates.

Ingen Technologies, Inc. (Pink Sheets: IGNT) announced today that it has signed a definitive sales agreement with Healthstar Associates Incorporated to expand distribution throughout the mid-west U.S. ( http://healthstarassociates.com/).

Healthstar Associates is a Regional Medical Sales and Marketing company headquartered in Lincolnwood, Illinois and doing business for almost 20 years. Healthstar Associates has a long history as a responsive, knowledgeable manufacturers’ representative in the Midwest and Canada; functioning as a sales and marketing force for a wide range of medical manufacturers. Healthstar will target the respiratory markets including already established sales channels with hospitals, DME’s, Medical Suppliers, Nursing Facilities, Assisted Living and Home Care Providers.

“Unlike a typical U.S. or Canadian firm that specializes in a narrow segment of the healthcare market, says Barry Petrigala, President and Founder, “we’ve proven our ability to effectively reach a broader spectrum of markets which include: Hospitals, Home Healthcare, Nursing homes, Occupational health, Physical therapists, Fire/safety, Physicians, Rehabilitation, Chiropractors and Dental markets.”

“We are very pleased to welcome the Healthstar team to Ingen Technologies,” stated Scott R. Sand, CEO and Chairman of the Board of Ingen Technologies. “The new sales contract with Healthstar Associates is another significant step in the continued evolution of our product sales and product recognition.”

Over the past several months, the company has obtained an ISO certification to sell internationally, through its partnership with the KGMA who has registered Ingen with the CCR to sell to the U.S. Department of Defense, signed contracts with MediGroup Physician Services, and has attended several conferences to drum up business in all of its segments. As a result, Ingen has projected that its total 2010 sales will reach $11 million this year, supported by growth in these government, commercial and international export market opportunities.

Investors can review our current fact sheet at the following link:

http://www.ingen-tech.com/PDFbin/FactSheet.pdf

www.ingen-tech.com

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Tags: NASDAQ:LNCR, NYSE:CAH, PINK:IGNT
Posted in News | No Comments »

Ingen Technologies (IGNT) Should Unleash Significant Growth

Wednesday, September 1st, 2010

Ingen Technologies, Inc. (Pink Sheets: IGNT) appears to be properly positioned and ready to rapidly scale its business to the likes of other medical device makers, like Thoratec Corporation (Nasdaq: THOR) and Abiomed, Inc. (Nasdaq: ABMD), after securing key government licenses and preparing its products for export. With all barriers now removed, investors look forward to additional contracts and increased revenues.

The emerging medical device manufacturer focused on the respiratory industry has developed unique oxygen cannulas that improve patient comfort and reduce provider support costs. Since Ingens’ cannulas are priced at roughly the same cost as traditional cannulas, yet offer piece of mind for the patient knowing that oxygen is flowing, the company is well-positioned to capture significant market share in the $400-500 million per year oxygen cannula industry.

One of the key barriers to bringing their products to market was the lack of appropriate licensing to conduct government and export sales. But recently, Ingen has acquired both of these licenses and projected that it is on track to realize $1.4 million in initial sales by the end of the year. This makes IGNT a stock that is certainly worth watching for investors looking for growth opportunities.

Ingen Secures Registration for Military Sales

On August 30, 2010, Ingen announced that it received a letter of confirmation from the Armed Services Association in Washington, D.C. stating that it is now registered with the U.S. Central Contractor Registry (CCR), which qualifies it to do business with the U.S. Department of Defense. Inclusion in the U.S. Military Purchasing Directory will put its products in front of potential military customers.

Meanwhile, the company has also been embarking on a number of military conferences designed to drum up interest and showcase its products to prospective buyers. Recently, its partner, KGMA, announced that it successfully demonstrated Ingen’s products at the 13th Annual Force Health Protection Conference in Arizona. Ingen has scheduled additional conferences for later this year.

In May 2010, KGMA also provided a field study showing that approximately 60 facilities would purchase $1.2 million of Ingen’s respiratory products over the next three to four months. KGMA visited these facilities on behalf of Ingen and demonstrated the new Oxyview and Smart Nasal Cannula, while noting that these facilities indicated interest in buying the products.

Ingen Attains ISO Certification to Sell Internationally

In March of 2010, Ingen also obtained certification under the ISO 13485, which enables it to sell internationally. With COPD projected to become the third largest killer in the developed world by 2020, the end markets for oxygen cannulas continues to rapidly expand. As one of the only innovators in the field, Ingen’s cannulas offer a clear value proposition and could capture a significant market share.

The ISO certification opens the door to deliver on existing backorders to countries in Europe and Asia, as well as countries like Canada and Australia.

Conclusions

Ingen has projected that its total 2010 sales will reach $11 million, supported by growth in military, commercial and international market opportunities. With all of its necessary certifications in line, investors can now look forward to the company executing on its plans and delivering value to shareholders.

Tags: NASDAQ:ABMD, NASDAQ:THOR, PINK:IGNT
Posted in Insights | No Comments »

Ingen Technologies Receives “Green Light” to Target U.S. Military With Innovative Patented Medical Product Line

Monday, August 30th, 2010

Ingen Technologies (Pink Sheets: IGNT), a medical device manufacturer focused on the respiratory market alongside companies like C.R. Bard, Inc. (NYSE: BCR) and ArthroCare Corporation (Nasdaq: ARTC), is now listed in Central Contractor Registry, which could pave the way towards an initial $1.4 million in sales.

Ingen Technologies, Inc. (Pink Sheets: IGNT), a medical device manufacturer with an emerging new medical product line targeting the $8 billion respiratory market, announced today that it has received a letter of confirmation from the Armed Services Association in Washington, D.C. stating that the company is now registered with the U.S. Central Contractor Registry (CCR), which qualifies it to do business with the U.S. Department of Defense (DoD).

The United States Military Purchasing Directory is distributed to all purchasing offices throughout the DoD every fiscal year. Purchasing officers and DoD contracting personnel specifically use the directory to locate vendors from whom they will buy goods and services. This directory now includes Ingen Technologies Inc.

After visiting 60 military facilities and introducing Ingen’s new respiratory product line that includes 2 models of the Oxyview flow meter and and 6 new models of the Smart Nasal Cannulas, KGMA Business Solutions previously projected that approximately 60 military facilities had an interest in allocating unspent funds to purchase $1.4 million worth of the respiratory products by the end of this year.

“After successfully registering with the CCR, Ingen is now rapidly expanding its sales in the U.S. military marketplace,” said Ingen Chairman and CEO Scott R. Sand. “We look forward to our upcoming conference on September 8, 2010 in Frederick, Maryland, as we continue our expansion efforts.”

Investors can review our current fact sheet at the following link:

http://www.ingen-tech.com/PDFbin/FactSheet.pdf

Company Websites:

http://www.ingen-tech.com/

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010, the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at:

http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements:
This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Tags: NASDAQ:ARTC, NYSE:BCR, PINK:IGNT
Posted in News | No Comments »

Ingen Technologies, Inc. Products Fill Key Void for Medical Distributor

Monday, August 23rd, 2010

Ingen Technologies, Inc. (Pink Sheets: IGNT), an emerging medical device manufacturer, similar to companies like Medtronic, Inc. (NYSE: MDT) and Boston Scientific Corporation (NYSE: BSX) , announced that its Smart Nasal Cannula with Oxyview and Fingertip Pulse Oxymeter solutions fill a void for Mountainside Medical Equipment customers.

Ingen Technologies, Inc. (Pink Sheets: IGNT), an emerging medical device manufacturer developing innovating proprietary solutions for the $8 billion respiratory market, today announced that its products have filled a key void for Mountainside Medical Equipment (www.mountainside-medical.com), a veteran-owned worldwide distributor of medical supplies based in Upstate New York.

“For decades, our customers have requested a product allowing for simpler, more accurate monitoring of oxygen as provided by their concentrator or tank,” said Marty Zarnock, Jr., Vice President of Mountainside Medical Equipment. “The Smart Nasal Cannula with Oxyview is now available to meet those demands, as nursing homes, hospital residents and at-home patients can now confidently receive oxygen safety and accurately as prescribed by their medical provider with these two products.”

“The Ingen Fingertip Pulse Oximeter has also proven to be an asset in respiratory monitoring at Mountainside. With its large and bright LCD display, colorful, compact design, our customers’ satisfaction and sales have improved tremendously. This product addition allows us to offer our customers a high-quality, state-of-the-art oximetry product at competitive pricing. The Mountainside team looks forward to further promotion of these products and the introduction of new products with similar success,” he added.

Ingen’s Smart Nasal Cannula uses the Oxyview Technology that is patented and proprietary. It monitors the actual flow of oxygen nearest the patient. The product has proven to reduce service calls while at the same time provides safety and assurance directly to the patient. The company projects to increase its sales over the next 12 months while targeting export sales to China, Canada, Australia and Europe.

With approximately 23 million patients in the U.S., and an estimated 600 million patients worldwide, who suffer from chronic obstructive pulmonary disease (COPD), Ingen stands to capture $200 million in revenues over the next five years. Since an average COPD patient uses two to three nasal cannulas each month to prevent bacteria build-up within the device, there is a growing and recurring demand for the product that benefits Ingen’s top and bottom line results.

“After reporting a successful quarter earlier this month, we have been focused on rapidly expanding our sales efforts and attracting high quality distributors like Mountainside Medical Equipment,” said Ingen CEO Scott Sand. “We are pleased to be working with one of the top medical supply companies on Google throughout the United States and Canada and we look forward to similar agreements going forward.”

Investors can review our current fact sheet at the following link:

http://www.ingen-tech.com/PDFbin/FactSheet.pdf

Company Websites:

http://www.ingen-tech.com

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Mountainside Medical Equipment:
In the past three decades our values have stayed the same, great pricing, quick deliveries, and excellent customer service. Mountainside Medical has positioned itself in the medical supplies industry to service both the hospital and home care patients with products reflecting both innovation and exceptional price. Your continued support of our products has allowed us to grow and offer you the best pricing in the healthcare industry today. Whether you are a longtime friend or a new one, we will always welcome you and look forward to providing you the very best cost effective products and service possible. We are family-owned small business located in Upstate New York located at the base of the Adirondack Mountain’s.

About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements:

This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Tags: NYSE:BSX, NYSE:MDT, PINK:IGNT
Posted in News | No Comments »

Ingen (IGNT) Reports Increases in Sales and Assets in Latest Annual Report

Friday, August 6th, 2010

Ingen Technologies, Inc. (IGNT), an emerging medical device manufacturer, similar to companies like Alphatec Holdings (ATEC) and C.R. Bard (BCR), announced the release of its latest annual report, which highlighted increases in sales and assets during fiscal 2010.

Ingen Technologies, Inc. (OTCMarkets: IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8 billion respiratory market, today announced that its Annual Report has been filed with the OTC Markets, while auditors have completed and filed required restatements needed to return to “fully reporting” status.

The Annual Report confirms that Ingen has filed two additional patents to protect its intellectual property, including a foreign patent during 2010. In addition, the report indicates that the company successfully achieved ISO 13485:2003 Certification as a requirement to sell its products outside the USA. Other highlights in the report discuss the GSA filing and progress made with regards to government contracts in VA Hospitals and the Department of Defense.

Ingen reported a 1,200% increase in sales to $128,917, compared to $10,401 in 2009, and an 865% increase in gross profit to $83,314, compared to $9,631 in fiscal 2009. The company’s assets increased 227% to $497,124, compared to $218,415 in fiscal 2009, while its debt owed to note holder(s) decreased 60% from $5,000,000 to $2,000,000 since fiscal 2009. Finally, cash reserves increased 635% to $268,551, compared to $42,272 in fiscal 2009.

The company’s auditing firm, Anton & Chia LLP, has completed the auditing required for Ingen to move forward towards achieving “fully reporting” status. On October 29, 2009 (the “Engagement Date”), the Registrant engaged Anton & Chia, LLP (“A&C”) as its independent registered public accounting firm for the Registrant’s fiscal year ended May 31, 2009. The decision to engage A&C as the Registrant’s independent registered public accounting firm was approved by the Registrant’s Board of Directors. Anon & Chia have now begun working on the 10-QSB’s ending August 31, 2009, November 30, 2009, and February 28, 2010, as well as will complete and file the 10-KSB ending May 31, 2010.

“Ingen is diligently working to achieve rapid sales growth in both the U.S. and abroad, while balance sheet improvements give us the flexibility needed to truly unlock value for our shareholders,” said Ingen Technologies, Inc. CEO Scott Sand. “Our initial government sales contract can be signed later this month, as we reach for the $1.4 million available through various government facilities for the remaining of this year. In addition, we continue pushing towards becoming a fully reporting, uplisted company by the end of this year.”

The Annual Report Ending May 31, 2010 is available at the following link:

http://www.otcmarkets.com/stock/IGNT/financials

Investors can review our current fact sheet at the following link:

http://www.ingen-tech.com/PDFbin/FactSheet.pdf

Company Websites:

http://www.ingen-tech.com

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen:

Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Tags: NASDAQ:ATEC, NASDAQ:BCR, PINK:IGNT
Posted in News | No Comments »

Ingen (IGNT) Passes ISO Six-Month Review

Thursday, August 5th, 2010

Ingen Technologies, Inc., an emerging medical device manufacturer, similar to companies like Alphatec Holdings (ATEC) or Myriad Genetics (MYGN), announced that it successfully passed its six-month ISO audit.

Ingen Technologies, Inc. (OTCMarkets: IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8 billion respiratory market, reported today that the company successfully passed their six-month ISO audit.

According to Jeffrey Tuthill, the auditor for BSI America, on August 4, 2010 his report stated “Ingen Technologies’ capability to systematically meet agreed requirements for products and services supplied within the scope of the certificate is confirmed, and Ingen meets the applicable requirements of the ISO13485:2003, part 1 of CMDR, and of the MDD 93/42/EEC, Annex V (M5).” You can learn about BSI at the following link: http://www.bsiamerica.com/en-us/Assessment-and-Certification-services/

“The company continues to progress with its sales and marketing program. We are required to maintain International Standards Organizations (ISO) certification in order to sell our products outside the United States. We believe that the export markets for Canada, Asia, Europe and Australia are much larger than the market in the USA.” said Ingen Technologies CEO Scott Sand.

Investors can review our current fact sheet at the following link:

http://www.ingen-tech.com/PDFbin/FactSheet.pdf

Company Websites:

http://www.ingen-tech.com

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Tags: NASDAQ:ATEC, NASDAQ:MYGN, PINK:IGNT
Posted in News | No Comments »

Ingen (IGNT) Files Patent and Gears Up to Produce New Medical Product

Friday, July 16th, 2010

Ingen Technologies, Inc. (IGNT), a medical device maker focused on the respiratory and now diabetes markets, operating alongside companies like Inverness Medical Innovations, Inc. (IMA) and OSI Pharmaceuticals, Inc. (OSIP), announced that it has filed a US patent and will begin the required manufacturing processes to product the new drug insulin thermos product.

Ingen Technologies, Inc. (OTCMarkets: IGNT.PK), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company has also filed a US patent and will begin the required manufacturing processes to produce the new drug insulin thermos product.

Diabetes effects approximately 170 million people worldwide and is increasing, with the World Health Organization predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates. The Global Diabetes drugs treatment market was valued of $15 billion in 2005. Oral anti-diabetics were the leading category of drugs – $8.19 billion – and showed a growth rate of 6.3% from the total global sales in 2004. The total sales for insulin products increased by 16.5% to total global sales of $6.83 billion in 2004.

The new drug insulin thermos will allow patients to port their glass vials of liquid insulin within a small protective container. The container will be cooled by recharged polymer crystals, and will display the inside temperature of the container. The liquid insulin, tablets and other liquid drugs that use glass vials must be maintained at a cool temperature between 60-78 degrees (F) in order to prevent molecular breakdown of the compounds that allow the drug to be effective. Ingen’s device will be compact to fit in a shirt pocket or briefcase, and will keep the contents cool for 8-12 hours. The unit can be plugged into a 12volt system, such as a car, boat or plane, and recharged to keep the contents cooled. The proprietary technologies used to produce and monitor the temperature is a microprocessor chip.

The device will not require FDA registration and will allow for faster market penetration. Market acceptance could be very high, and the product can be sold over-the-counter to patients as well as sold to the 6,000 hospitals in the U.S.

Over the past 30 years, studies have shown that the prevalence of diabetes in China was gradually rising trend. At present, China faces new problems: the world’s largest diabetes populations. China now has 92 million diabetic patients. The World Health Organization estimated in 2006 to 2015, diabetes, heart disease and stroke will cost China 558 billion U.S. dollars.

“With this new product we will broaden our portfolio of innovative insulin support technologies and strengthen our position to be a new player in the diabetes care business,” said Scott Sand, CEO. Sand further stated, “We are already manufacturing respiratory products and the company is ISO certified with a DHS license to manufacture medical product. We anticipate starting right away to design the tooling and production processes. The device is mold injected and can be massed produced very easily. Product pricing is expected to be at $45 per unit with COGS at $8 per unit. The margins and projected gross profits are generous.”

Investors can review our current fact sheet at the following link:

http://www.ingen-tech.com/PDFbin/FactSheet.pdf

www.ingen-tech.com

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Tags: NASDAQ:OSIP, NYSE:IMA, PINK:IGNT
Posted in News | No Comments »

Ingen Technologies (IGNT) Gears Up to Fight $40 Billion COPD Epidemic

Thursday, July 15th, 2010

Ingen Technologies Inc. (IGNT.PK), an emerging medical device maker developing innovative solutions for the respiratory market, could distribute to larger in-home care companies such as Lincare Holdings, Inc. (LNCR) and Cardinal Health, Inc. (CAH).

According to the World Health Organization (WHO), Chronic Obstructive Pulmonary Disease (COPD) kills an estimated average of one person every 10 seconds. WHO estimates that 80 million people have moderate to severe COPD. In 2005, COPD contributed to 5% of deaths worldwide.

WHAT IS COPD?

COPD is defined as a lung ailment that is characterized by a persistent blockage of airflow from the lungs. WHO claims that, “it is an under-diagnosed, life-threatening lung disease.” The lung disease cannot be cured, but proper treatment may help slow progression of the disease. WHO estimates have predicted 210 million people worldwide have COPD, and that 3 million people died of COPD in 2005. The illness is currently the 4th leading cause of death in the U.S., and the market consumes an estimated $42.6 billion due to health care costs and lost productivity. According to the Center for Disease Control (CDC), COPD related deaths are experiencing a 16% growth rate. Analysts predict an increase of COPD related deaths over the next 20 years, resulting in the third leading cause of death worldwide.

DIAGNOSIS AND TREATMENT

COPD diagnosis is achieved when utilizing the “spirometry” test. The “spirometry test measures the rate and volume at which air can move in and out of the lungs. As mentioned above, the disease cannot be cured but proper treatment can be applied. Effective treatment procedures allow COPD patients to achieve a higher quality of life. When using oxygen tanks and various medicines, patients can slow the progression of COPD.

COMPANIES WHO ASSIST IN SLOWING THE PROGRESSION OF COPD!

Ingen Technologies, Inc. (IGNT.PK) has grown to become the largest manufacturer of gravity-independent in-line oxygen flow meters since the introduction of their patented Oxyview cannula respiratory device. This unique oxygen flow meter provides respiratory patients the ability to place an accurate oxygen flow measurement at all times, ensuring constant oxygen flow. These in-home products provide insurance companies the ability to minimize home care service calls, which in turn reduces insurance costs.

The Nasal Cannula was designed to achieve the following:

1) Installation of flow-meter at minimal cost
2) No batteries required
3) Fixed to fit all respiratory devices
4) Provide measurement of oxygen flow
5) Gravity independent
6) Use of commercial or residential

Lincare Holding Inc. (NASDAQ:LNCR) provides patients with oxygen products, as well as other therapy services related to respiratory illness. Operational focus is primarily structured around serving those customers with a demand for oxygen based products. LNCR products range from oxygen equipment, oxygen concentrators, liquid oxygen systems, as well as other respiratory therapy services. LNCR focuses on a mission to provide high quality health products to patients at home.

Cardinal Health, Inc. (NYSE:CAH) specializes in providing medical device products and services to the health care industry. The company is involved in three segments, which include pharmaceuticals, medical and carefusion. The company delivers various health products which include enteral devices and airway management products.

SUMMARY

COPD illness is on a continuous growing curve. The COPD disease cannot be cured, but treatments may assist in slowing disease progression. Also the COPD market is growing every year. Therefore, demand for oxygen and other respiratory products may continue to increase. Companies like IGNT, CAH and LNCR are helping to meet this growing demand which investors are taking note on.

Tags: NASDAQ:LNCR, NYSE:CAH, PINK:IGNT
Posted in Insights | No Comments »

Ingen (IGNT) CEO Interviewed on Money Channel

Thursday, July 15th, 2010

Ingen Technologies, Inc. (OTCMarkets: IGNT.PK), an emerging medical device manufacturer developing innovative solutions for the respiratory market and companies like Lincare Holdings (LNCR) and Cardinal Health, Inc. (CAH), with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company’s CEO, Scott Sand, will talk on the live radio program of The Money Channel’s American Scene Radio with host Steve Crowley today at 11:49am eastern standard time.

According to the World Health Organization (WHO), Chronic Obstructive Pulmonary Disease (COPD) kills an estimated average of one person every 10 seconds. In 2005, COPD contributed to 5% of deaths worldwide.

Ingen’s strategic consulting partner for government contract procurement, KGMA Business Solutions, has introduced the new Smart Nasal Cannula to various military and government branches. Kenneth Kurk, President of the Texas based KGMA Business Solutions has indicated in a written report that there is $1.4M dollars made available before the end of this year for the Ingen products with the various branches they have visited. Mr. Kurk and his highly experienced staff are pushing to close purchase contracts for Ingen.

“Companies like Ingen are helping to meet this growing demand which investors are taking note on.” Stated Scott Sand, CEO and Chairman of the Board. Sand further stated “Although our commercial sales are increasing as we ship products everyday to patients, government VA Hospitals provide medical care to literally millions of veterans ranging from young adults to seniors. Many of these veterans suffer from COPD and utilize home oxygen services provided through the government. Our new Smart Nasal Cannula will be recognized to improve the home oxygen therapy for these patients and provide other benefits such as a reduction in service calls and equipment problems related to home oxygen therapy. There is also interest with the Department of Defense regarding using our medical product with Army facilities. Our larger market is export sales for Europe and Asia. We have recently demonstrated our management strength with our ISO Certification, and we anticipate receiving our CE Mark to sell our products and fulfill backorders for our export sales.”

Ingen announced on July 7th that the company’s strategic government contract consultant, KGMA Business Solutions, has scheduled two major tradeshows for August and September 2010. It will debut its new Smart Nasal Cannula on August 10-11, 2010 at the 13th Annual Force Health Protection Conference (FHP) in Phoenix, Arizona; and again on September 8th, 2010 at the Fort Detrick Vendor Day in Frederick, Maryland.

http://www.eventsinamerica.com/events/13th_annual_force_health_protection_conference/ev4a9c3043dc273/

http://www.detrick.army.mil/services/vendorday.cfmhttp://www.ingen-tech.com/

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Tags: NASDAQ:LNCR, NYSE:CAH, PINK:IGNT
Posted in News | No Comments »